A Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

Key Inclusion Criteria:

- Patients must have documented IDH1-R132 gene-mutated disease as evaluated by site

- Glioma: Advanced glioma that has recurred or progressed following standard therapy, or
that has not responded to standard therapy.

- Hepatobiliary cancer that is relapsed/refractory or intolerant to approved
standard-of-care therapy (included: hepatocellular carcinoma, bile duct carcinoma,
intrahepatic cholangiocarcinoma or other hepatobiliary carcinomas)

- Chondrosarcoma that is relapsed or refractory and either locally advanced or
metastatic and not amenable to complete surgical excision

- Intrahepatic cholangiocarcinoma that is advanced nonresectable or metastatic
cholangiocarcinoma not eligible for curative resection or transplantation. Phase
1b/Safety Lead-in of Phase 2: relapsed or refractory disease. Combination Phase 2
(beyond Safety Lead-in): have received no more than 1 cycle of gemcitabine/cisplatin
therapy

- Other solid tumors that have relapsed or refractory to standard-of-care therapy with
no other available therapeutic options

- Good performance status

- Good kidney and liver function

Key Exclusion Criteria:

- Prior solid organ or hematopoietic cell transplant

- Prior treatment with IDH1 inhibitor (Single agent cohorts only)

- Congestive heart failure (New York Heart Association Class III or IV) or unstable
angina pectoris. Previous history of myocardial infarction within 1 year prior to
study entry, uncontrolled hypertension or uncontrolled arrhythmias

- Unstable or severe, uncontrolled medical condition (e.g., unstable cardiac function,
unstable pulmonary condition including pneumonitis and/or interstitial lung disease,
uncontrolled diabetes)

- Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic
therapy

- PD-1 only: active autoimmune disease